🧬 This deal aims to enhance Fractyl’s Rejuva* pancreatic gene therapy platform, targeting obesity and type 2 diabetes.
🏭 Forge’s FUEL™ platform will facilitate scalable manufacturing solutions.
🔬 All operations will occur at Forge’s 200,000 sq. ft. facility in Columbus, OH.
📈 This collaboration supports innovative treatments for metabolic diseases.
Introduction:
Forge Biologics has recently established a strategic partnership with Fractyl Health, aimed at developing and manufacturing adeno-associated viral (AAV) vectors. This agreement is poised to accelerate the advancement of Fractyl’s innovative Rejuva* pancreatic gene therapy platform, targeting obesity and type 2 diabetes—a growing public health concern worldwide.
- Forge Biologics will provide process development and cGMP manufacturing services to Fractyl Health for their pancreatic gene therapy platform.
- The partnership utilizes Forge’s FUEL™ platform, which offers an efficient and scalable manufacturing solution for AAV vectors.
- Fractyl Health’s CEO highlighted the importance of Forge’s manufacturing capabilities in developing sustainable therapies for metabolic diseases.
- The collaboration will take place at Forge’s state-of-the-art manufacturing facility in Columbus, Ohio, which spans 200,000 square feet.
- This deal not only enhances Fractyl’s developmental capabilities but also signifies Forge’s commitment to addressing metabolic disorders through innovative gene therapy solutions.
Conclusion:
The collaboration between Forge Biologics and Fractyl Health marks a significant stride towards innovative treatments for metabolic diseases, particularly obesity and type 2 diabetes. By combining Forge’s advanced manufacturing technologies with Fractyl’s gene therapy expertise, the partnership is set to deliver scalable therapeutic solutions. The implications of this partnership extend beyond immediate therapeutic developments, potentially shaping future strategies in the biomanufacturing landscape for metabolic disorders.
